RNXtract®

About Cerca Biotech

Cerca Biotech GmbH, founded in 2018 and headquartered in Berlin, Germany, is a commercial-stage diagnostics company specializing in women's health. Its core portfolio includes MammaTyper®, a molecular RT-qPCR test for breast cancer classification, and RNXtract®, a sample preparation product for FFPE tissue. The company is also developing CercaTest RED™, a point-of-care, non-invasive urine test for pre-eclampsia, positioning it at the intersection of precision oncology and rapid obstetric diagnostics. As a subsidiary of China's Shuwen Biotech, Cerca serves as the commercial gateway for these technologies in the European market.

Therapeutic Areas